Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.RSV.preF-based RSV Vaccine in Japanese Adults
jRCT2031210619Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2022
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Ad26.RSV.preF vaccine in respiratory syncytial virus disease (RSV) (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Cohort 1: RT-PCR confirmed RSV-mediated lower respiratory tract disease (LRTD) and Cohort 2: Neutralizing antibody titers against RSV A strain (VNA assay). Started Apr 2022; status: completed.
02
Drugs
Ad26.RSV.preF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031210619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210619.